CN103432137B - Medicinal composition of cefoxitin - Google Patents
Medicinal composition of cefoxitin Download PDFInfo
- Publication number
- CN103432137B CN103432137B CN201310381238.9A CN201310381238A CN103432137B CN 103432137 B CN103432137 B CN 103432137B CN 201310381238 A CN201310381238 A CN 201310381238A CN 103432137 B CN103432137 B CN 103432137B
- Authority
- CN
- China
- Prior art keywords
- cefoxitin
- ethanolamine
- sodium carbonate
- test
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002682 cefoxitin Drugs 0.000 title claims abstract description 72
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical group N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 title claims abstract 5
- 239000000203 mixture Substances 0.000 title abstract description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 84
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000012360 testing method Methods 0.000 abstract description 42
- 239000012535 impurity Substances 0.000 abstract description 12
- 229920000642 polymer Polymers 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 229940031098 ethanolamine Drugs 0.000 abstract 1
- 229940001593 sodium carbonate Drugs 0.000 abstract 1
- 238000013112 stability test Methods 0.000 abstract 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical group [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 70
- 239000000243 solution Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 7
- 238000004140 cleaning Methods 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229960003016 cefoxitin sodium Drugs 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001134775 Lysinibacillus fusiformis Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310381238.9A CN103432137B (en) | 2013-08-28 | 2013-08-28 | Medicinal composition of cefoxitin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310381238.9A CN103432137B (en) | 2013-08-28 | 2013-08-28 | Medicinal composition of cefoxitin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103432137A CN103432137A (en) | 2013-12-11 |
CN103432137B true CN103432137B (en) | 2015-01-28 |
Family
ID=49685923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310381238.9A Active CN103432137B (en) | 2013-08-28 | 2013-08-28 | Medicinal composition of cefoxitin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103432137B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582830A (en) * | 1982-09-10 | 1986-04-15 | Glaxo Group Limited | Pharmaceutical compositions |
CN101941983A (en) * | 2010-09-25 | 2011-01-12 | 海南天煌制药有限公司 | Preparation method of high-purity cefoxitin sodium |
CN102755325A (en) * | 2012-07-04 | 2012-10-31 | 深圳信立泰药业股份有限公司 | Cefoxitin sodium medicinal composition, powder injection and preparation method thereof |
-
2013
- 2013-08-28 CN CN201310381238.9A patent/CN103432137B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582830A (en) * | 1982-09-10 | 1986-04-15 | Glaxo Group Limited | Pharmaceutical compositions |
CN101941983A (en) * | 2010-09-25 | 2011-01-12 | 海南天煌制药有限公司 | Preparation method of high-purity cefoxitin sodium |
CN102755325A (en) * | 2012-07-04 | 2012-10-31 | 深圳信立泰药业股份有限公司 | Cefoxitin sodium medicinal composition, powder injection and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
李捷玮,等.《二乙醇胺、三乙醇胺》.《常用药物辅料手册》.2000,(第1版),第91-92、287-288页. * |
Also Published As
Publication number | Publication date |
---|---|
CN103432137A (en) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3970744A1 (en) | Stable secukinumab injection and preparation method therefor | |
CN102784382B (en) | Argatroban drug composition and preparation method and application of argatroban drug composition | |
CN101926840B (en) | Ultrafine powder of echinacea and preparation method and application thereof | |
CN105853351B (en) | Linezolid oral administration mixed suspension and preparation method thereof | |
CN108498469A (en) | Dexmedetomidine hydrochloride freeze-dried powder and preparation method thereof | |
CN106474048A (en) | A kind of more stable desonide gel preparation of quality | |
CN102481287A (en) | Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof | |
CN104208028A (en) | Faropenem sodium-containing granules and preparation method thereof | |
CN103432137B (en) | Medicinal composition of cefoxitin | |
CN105362235B (en) | Compound medicament composition of amoxicillin sodium and clavulanate potassium and preparation method thereof | |
CN110101670B (en) | Aztreonam injection preparation and preparation method thereof | |
WO2014040280A1 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
CN103159710B (en) | Antiviral decalin derivate | |
CN103432086B (en) | Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof | |
CN103565747B (en) | Esomeprazole composition and preparation method thereof | |
US20210228527A1 (en) | Busulfan composition, preparation method therefor and application thereof | |
CN104257618B (en) | Orally disintegrating tablet containing faropenem sodium and preparation method of orally disintegrating tablet | |
CN110437260B (en) | Cefuroxime sodium raw material, injection and preparation method thereof | |
CN102657646A (en) | Medicinal composition and preparation thereof | |
CN108186594A (en) | A kind of Montelukast sodium chewable tablet and preparation method thereof | |
JP2020516665A (en) | (E)-2,6-dialkoxystyryl 4-substituted benzylsulfone formulations with improved stability and bioavailability for administration | |
CN107823130A (en) | A kind of preparation method of tetrandrine injection agent medicine composition | |
CN102727429B (en) | Pidotimod injection with modified stability, and preparation method thereof | |
CN107137374B (en) | Solid pharmaceutical composition of palonosetron | |
CN102058602A (en) | Stable oral solid preparation containing losartan potassium and hydrochlorothiazide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20131211 Assignee: Hainan Tianhuang Pharmaceutical Co.,Ltd. Assignor: Lu Hongdai Contract record no.: 2015460000002 Denomination of invention: Medicinal composition of cefoxitin Granted publication date: 20150128 License type: Exclusive License Record date: 20150423 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Lu Hongdai Inventor after: Deng Zixin Inventor before: Lu Hongdai |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180403 Address after: 570203 North Road, Meilan District, Haikou, Hainan Province, No. 6 Patentee after: Hainan Tianhuang Pharmaceutical Co.,Ltd. Address before: No. 6 North Road, Meilan District, Haikou, Hainan Patentee before: Lu Hongdai |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition of cefoxitin Effective date of registration: 20180428 Granted publication date: 20150128 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Tianhuang Pharmaceutical Co.,Ltd. Registration number: 2018460000002 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220222 Granted publication date: 20150128 Pledgee: China Everbright Bank Co.,Ltd. Haikou Branch Pledgor: Hainan Tianhuang Pharmaceutical Co.,Ltd. Registration number: 2018460000002 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220818 Address after: 311400 1278 Gongwang street, Fuchun street, Fuyang District, Hangzhou City, Zhejiang Province Patentee after: ZHEJIANG WHITESON PHARMA Co.,Ltd. Address before: 570203 No. 6 Airport North Road, Meilan District, Hainan, Haikou Patentee before: Hainan Tianhuang Pharmaceutical Co.,Ltd. |